PAGITANE
LOE ApproachingNDAORALTABLET
Approved
Jul 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PAGITANE is an oral small-molecule tablet approved by Eli Lilly in 1953 for an undisclosed indication. The specific mechanism of action and therapeutic area are not documented in available data, limiting characterization of its clinical profile.
LOE Approaching
Product approaching loss of exclusivity with minimal current portfolio activity; brand team likely in maintenance or transition mode.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PAGITANE currently shows zero linked job openings, reflecting its mature, pre-LOE stage with minimal team expansion. Working on this product offers limited career acceleration; roles are primarily defensive, focused on maximizing remaining patent-protected revenue.
Brand ManagerCommercial Operations
Worked on PAGITANE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.